Treatment and prevention of enterococcal infections - Alternative and experimental approaches

Expert Opinion on Biological Therapy

Volumn 4, Issue 9, 2004, Pages 1519-1531

  Koch, Stefanie ^a   Hufnagel, Markus ^b   Huebner, Johannes ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Bacteriophage therapy; Biofilm; Enterococci; Probiotics; Therapeutic antibodies; Vaccine; Virulence factors

Indexed keywords

ABC TRANSPORTER; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; COTRIMOXAZOLE; CYTOLYSIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DNA VACCINE; LINEZOLID; N (5 FLUORO 1 OXIDO 2 PYRIDINYL) 1 [2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANOYL]PROLINAMIDE; ORITAVANCIN; PENICILLIN DERIVATIVE; POLYSACCHARIDE; PROBIOTIC AGENT; STREPTOGRAMIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN; VIRULENCE FACTOR; VITACANIS;

ANIMAL MODEL; ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BACTERIOPHAGE; BACTERIOPHAGE THERAPY; BIOFILM; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; HUMAN; INFECTION CONTROL; LACTOBACILLUS ACIDOPHILUS; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SACCHAROMYCES CEREVISIAE; SIDE EFFECT; VACCINATION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; BACTERIOPHAGES; BIOFILMS; BIOLOGICAL THERAPY; CROSS INFECTION; DRUG RESISTANCE; ENTEROCOCCUS; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; PROBIOTICS; VACCINATION;

ANIMALIA; BACTERIA (MICROORGANISMS); ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; SACCHAROMYCES; SACCHAROMYCES CEREVISIAE;

EID: 4544301204     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.9.1519     Document Type: Review

References (139)

1. FRANZ CM, STILES ME, SCHLEIFER KH, HOLZAPFEL WH: Enterococci in foods-a conundrum for food safety. Int. J. Food Microbiol. (2003) 88(2-3):105-122.
2. KAYSER FH: Safety aspects of enterococci from the medical point of view. Int. J. Food Microbiol. (2003) 88(2-3):255-262.
3. RICE EW, MESSER JW, JOHNSON CH, REASONER DJ: Occurrence of high-level aminoglycoside resistance in environmental isolates of enterococci. Appl. Environ. Microbiol. (1995) 61(1):374-376.
4. RICHARDS MJ, EDWARDS JR, CULVER DH, GAYNES RP: Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit. Care Med. (1999) 27(5):887-892.
5. LANDRY SL, KAISER DL, WENZEL RP: Hospital stay and mortality attributed to nosocomial enterococcal bacteremia: a controlled study. Am. J. Infect. Control (1989) 17(6):323-329.
6. CHANG S, SIEVERT DM, HAGEMAN JC et al.: Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med. (2003) 348(14):1342-1347. First report demonstrating the transfer of antibiotic resistance from a vancomycin-resistant enterococcus to a S. aureus strain in a clinical setting.
7. MONTECALVO MA, HOROWITZ H, GEDRIS C et al.: Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob. Agents Chemother. (1994) 38(6):1363-1367.
8. PAPANICOLAOU GA, MEYERS BR, MEYERS J et al.: Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: risk factors for acquisition and mortality. Clin. Infect. Dis. (1996) 23(4):760-766.
9. ORLOFF SL, BUSCH AM, OLYAEI AJ et al.: Vancomycin-resistant Enterococcus in liver transplant patients. Am. J. Surg. (1999) 177(5):418-422.
10. D'AGATA EM, GREEN WK, SCHULMAN G et al.: Vancomycin-resistant enterococci among chronic hemodialysis patients: a prospective study of acquisition. Clin. Infect. Dis. (2001) 32(1):23-29.
11. ROGHMANN MC, FINK JC, POLISH L et al.: Colonization with vancomycin-resistant enterococci in chronic hemodialysis patients. Am. J. Kidney Dis. (1998) 32(2):254-257.
12. OSTROWSKY BE, VENKATARAMAN L, D'AGATA EM et al.: Vancomycin-resistant enterococci in intensive care units: high frequency of stool carriage during a non-outbreak period. Arch. Intern. Med. (1999) 159(13):1467-1472.
13. HAYDEN MK: Insights into the epidemiology and control of infection with vancomycin-resistant enterococci. Clin. Infect. Dis. (2000) 31(4):1058-1065.
14. NO AUTHORS LISTED: CDC: reports of VRE cases increasing; hepatitis vaccinations improving. Nephrol. News Issues (1999) 13(5):31, 36-37.
15. EDMOND MB, OBER JF, DAWSON JD, WEINBAUM DL, WENZEL RP: Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin. Infect. Dis. (1996) 23(6):1234-1239.
16. HANCOCK LE, GILMORE MS: Pathogenicity of Enterococci. In: Gram-Positive Pathogens. Fischetti VA, Novick RP, Ferretti JJ, Portnoy DA, Rood JI (Eds), ASM Press, Washington DC, USA (2000):251-258.
17. HUYCKE MM, SAHM DF, GILMORE MS: Multiple-drug resistant enterococci: the nature of the problem and an agenda for the future. Emerg. Infect. Dis. (1998) 4(2):239-249.
18. KAUFFMAN CA: Therapeutic and preventative options for the management of vancomycin-resistant enterococcal infections. J. Antimicrob. Chemother. (2003) 51(Suppl. 3):iii23-iii30.
19. UTTLEY AH, COLLINS CH, NAIDOO J, GEORGE RC: Vancomycin-resistant enterococci. Lancet (1988) 1(8575-8576):57-58.
20. LECLERCQ R, DERLOT E, DUVAL J, COURVALIN P: Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N. Engl. J. Med. (1988) 319(3):157-161.
21. SAHM DF, KISSINGER J, GILMORE MS et al.: In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis. Antimicrob. Agents Chemother. (1989) 33(9):1588-1591.
22. ARTHUR M, COURVALIN P: Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob. Agents Chemother. (1993) 37(8):1563-1571.
23. HAYDEN MK, TRENHOLME GM, SCHULTZ JE, SAHM DF: In vivo development of teicoplanin resistance in a VanB Enterococcus faecium isolate. J. Infect. Dis. (1993) 167(5):1224-1227.
24. KAWALEC M, GNIADKOWSKI M, KEDZIERSKA J et al.: Selection of a teicoplanin-resistant Enterococcus faecium mutant during an outbreak caused by vancomycin-resistant enterococci with the vanB phenotype. J. Clin. Microbiol. (2001) 39(12):4274-4282.
25. HACKER J, KAPER JB: Pathogenicity islands and the evolution of microbes. Annu. Rev. Microbiol. (2000) 54:641-679.
26. SHANKAR N, BAGHDAYAN AS, GILMORE MS: Modulation of virulence within a pathogenicity island in vancomycin-resistant Enterococcus faecalis. Nature (2002) 417(6890):746-750. First report of a large pathogenicity island un enterococci.
27. MURRAY BE: Vancomycin-resistant enterococcal infections. N. Engl. J. Med. (2000) 342(10):710-721.
28. DIBO I, PILLAI SK, GOLD HS et al.: Linezolid-resistant Enterococcus faecalis isolated from a cord blood transplant recipient. J. Clin. Microbiol. (2004) 42(4):1843-1845.
29. BOZDOGAN B, APPELBAUM PC: Oxazolidinones: activity, mode of action, and mechanism of resistance. Int. J. Antimicrob. Agents (2004) 23(2):113-119.
30. JORGENSEN JH, CRAWFORD SA, KELLY CC, PATTERSON JE: In vitro activity of daptomycin against vancomycin-resistant enterococci of various Van types and comparison of susceptibility testing methods. Antimicrob. Agents Chemother. (2003) 47(12):3760-3763.
31. GONZALES RD, SCHRECKENBERGER PC, GRAHAM MB et al.: Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet (2001) 357(9263):1179.
32. HERRERO IA, ISSA NC, PATEL R: Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N. Engl. J. Med. (2002) 346(11):867-869.
33. ZIMMER SM, CALIENDO AM, THIGPEN MC, SOMANI J: Failure of linezolid treatment for enterococcal endocarditis. Clin. Infect. Dis. (2003) 37(3):e29-e30.
34. BASSETTI M, FARREL PA, CALLAN DA, TOPAL JE, DEMBRY LM: Emergence of linezolid-resistant Enterococcus faecium during treatment of enterococcal infections. Int. J. Antimicrob. Agents (2003) 21(6):593-594.
35. JONES RN, MOET GJ, SADER HS, FRITSCHE TR: Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates. J. Antimicrob. Chemother. (2004) 53(5):804-807.
36. CARPENTER CF, CHAMBERS HF: Daptomycin: another novel agent for treating infections due to drug-resistant Gram-positive pathogens. Clin. Infect. Dis. (2004) 38(7):994-1000.
37. GUAY DR: Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria. Pharmacotherapy (2004) 24(1):58-68.
38. LIEBERMAN JM: Appropriate antibiotic use and why it is important: the challenges of bacterial resistance. Pediatr. Infect. Dis. J. (2003) 22(12):1143-1151.
39. PATEL R: Clinical impact of vancomycin-resistant enterococci. J. Antimicrob. Chemother. (2003) 51(Suppl. 3):iii13-iii21.
40. TRICK WE, PAULE SM, CUNNINGHAM S et al.: Detection of vancomycin-resistant enterococci before and after antimicrobial therapy: use of conventional culture and polymerase chain reaction. Clin. Infect. Dis. (2004) 38(6):780-786.
41. KE D, PICARD FJ, MARTINEAU F et al.: Development of a PCR assay for rapid detection of enterococci. J. Clin. Microbiol. (1999) 37(11):3497-3503.
42. VOLLAARD EJ, CLASENER HA: Colonization resistance. Antimicrob. Agents Chemother. (1994) 38(3):409-414.
43. DONSKEY CJ, HANRAHAN JA, HUTTON RA, RICE LB: Effect of parenteral antibiotic administration on persistence of vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract. J. Infect. Dis. (1999) 180(2):384-390.
44. DONSKEY CJ, CHOWDHRY TK, HECKER MT et al.: Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N. Engl. J. Med. (2000) 343(26):1925-1932.
45. EDMOND MB, OBER JF, WEINBAUM DL et al.: Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin. Infect. Dis. (1995) 20(5):1126-1133.
46. HUEBNER J, WANG Y, KRUEGER WA et al.: Isolation and chemical characterization of a capsular polysaccharide antigen shared by clinical isolates of Enterococcus faecalis and vancomycin-resistant Enterococcus faecium. Infect. Immun. (1999) 67(3):1213-1219.
47. WANG Y, HUEBNER J, TZIANABOS AO et al.: Structure of an antigenic teichoic acid shared by clinical isolates of Enterococcus faecalis and vancomycin-resistant Enterococcus faecium. Carbohydr. Res. (1999) 316(1-4):155-160.
48. HUEBNER J, QUAAS A, KRUEGER WA, GOLDMANN DA, PIER GB: Prophylactic and therapeutic efficacy of antibodies to a capsular polysaccharide shared among vancomycin-sensitive and - resistant enterococci. Infect. Immun. (2000) 68(8):4631-4636. Initial demonstration of success in prevention and treatment of a systemic enterococcal infection in mice using a vaccine targeting enterococcal capsule polysaccharides.
49. HUFNAGEL M, HANCOCK LE, KOCH S, THEILACKER C, GILMORE MS, HUEBNER JH: Serological and genetic diversity of capsular polysaccharides in Enterococcus faecalis. J. Clin. Microb. (2004) 42(6):2548-2557. Demonstrates limited number of structurally diverse capsular polysaccharides of enterococci, arguing for the feasibility of the development of a broadly reactive enterococcal vaccine.
50. XU Y, SINGH KV, QIN X, MURRAY BE, WEINSTOCK GM: Analysis of a gene cluster of Enterococcus faecalis involved in polysaccharide biosynthesis. Infect. Immun. (2000) 68(2):815-823.
51. HANCOCK LE, GILMORE MS: The capsular polysaccharide of Enterococcus faecalis and its relationship to other polysaccharides in the cell wall. Proc. Natl. Acad. Sci. USA (2002) 99(3):1574-1579.
52. LESINSKI GB, WESTERINK MA: Vaccines against polysaccharide antigens. Curr. Drug Targets Infect. Disord. (2001) 1(3):325-334.
53. GRAVEKAMP C, KASPER DL, PAOLETTI LC, MADOFF LC: Alpha C protein as a carrier for type III capsular polysacchatide and as a protective protein in group B streptococcal vaccines. Infect. Immun. (1999) 67(5):2491-2496.
54. VISCOUNT HB, MUNRO CL, BURNETTE-CURLEY D, PETERSON DL, MACRINA FL: Immunization with FimA protects against Streptococcus parasanguis endocarditis in rats. Infect. Immun. (1997) 65(3):994-1002. The protective effect of anti-FimA serum against Streptococcus parasanguis infection and the reactivity of this serum against FimA-like proteins of enterococci, implying new prospects in enterococcal treatments.
55. BURNIE J, CARTER T, RIGG G et al.: Identification of ABC transporters in vancomycin-resistant Enterococcus faecium as potential targets for antibody therapy. FEMS Immunol. Med. Microbiol. (2002) 33(3):179-189. Interesting approach to the development of an ABC transporter complex vaccine against enterococci using patient sera for the identification of relevant antibodies.
56. SENNA JP, ROTH DM, OLIVEIRA JS, MACHADO DC, SANTOS DS: Protective immune response against methicillin resistant Staphylococcus aureus in a murine model using a DNA vaccine approach. Vaccine (2003) 21(19-20):2661-2666.
57. LIGOZZI M, PITTALUGA F, FONTANA R: Modification of penicillin-binding protein 5 associated with high-level ampicillin resistance in Enterococcus faecium. Antimicrob. Agents Chemother. (1996) 40(2):354-357.
58. SULAKVELIDZE A, ALAVIDZE Z, MORRIS JG JR: Bacteriophage therapy. Antimicrob. Agents Chemother. (2001) 45(3):649-659.
59. SMITH HW, HUGGINS MB: Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J. Gen. Microbiol. (1982) 128(Pt 2):307-318.
60. MERRIL CR, BISWAS B, CARLTON R et al.: Long-circulating bacteriophage as antibacterial agents. Proc. Natl. Acad. Sci. USA (1996) 93(8):3188-3192.
61. SOOTHILL JS: Treatment of experimental infections of mice with bacteriophages. J. Med. Microbiol. (1992) 37(4):258-261.
62. BOGOVAZOVA GG, VOROSHILOVA NN, BONDARENKO VM: [The efficacy of Klebsiella pneumoniae bacteriophage in the therapy of experimental Klebsiella infection]. Zh. Mikrobiol. Epidemiol. Immunobiol. (1991) 4:5-8.
63. SAKANDELIDZE VM: [The combined use of specific phages and antibiotics in different infectious allergoses]. Vrach. Delo (1991) 3:60-63.
64. PIRISI A: Phage therapy-advantages over antibiotics? Lancet (2000) 356:1418.
65. BISWAS B, ADHYA S, WASHART P et al.: Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect. Immun. (2002) 70(1):204-210. A completely different approach to the treatment of enterococcal infections using bacteriophages to infect and kill the bacteria.
66. TUOHY KM, PROBERT HM, SMEJKAL CW, GIBSON GR: Using probiotics and prebiotics to improve gut health. Drug Discov. Today (2003) 8(15):692-700.
67. CEBRA JJ: Influences of microbiota on intestinal immune system development. Am. J. Clin. Nutr. (1999) 69(5):1046S-1051S.
68. ISOLAURI E: Probiotics in human disease. Am. J. Clin. Nutr. (2001) 73(6):1142S-1146S.
69. DUNNE C, MURPHY L, FLYNN S et al.: Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. Antonie Van Leeuwenhoek (1999) 76(1-4):279-292.
70. BECQUET P: EU assessment of enterococci as feed additives. Int. J. Food Microbiol. (2003) 88(2-3):247-254.
71. BENYACOUB J, CZARNECKI-MAULDEN GL, CAVADINI C et al.: Supplementation of food with Enterococcus faecium (SF68) stimulates immune functions in young dogs. J. Nutr. (2003) 133(4):1158-1162. A well-designed animal trial that convincingly demonstrates the immunological effects of enterococci as probiotics.
72. MAIA OB, DUARTE R, SILVA AM, CARA DC, NICOLI JR: Evaluation of the components of a commercial probiotic in gnotobiotic mice experimentally challenged with Salmonella enterica subsp. enterica ser. Typhimurium. Vet. Microbiol. (2001) 79(2):183-189.
73. HALL-STOODLEY L, COSTERTON JW, STOODLEY P: Bacterial biofilms: from the natural environment to infectious diseases. Nat. Rev. Microbiol. (2004) 2(2):95-108.
74. BENGMARK S, GARCIA DE LORENZO A, CULEBRAS JM: Use of pro-, pre- and synbiotics in the ICU-future options. Nutr. Hasp. (2001) 16(6):239-256.
75. OTTE JM, PODOLSKY DK: Functional modulation of enterocytes by Gram-positive and Gram-negative microorganisms. Am. J. Physiol. Gastrointest. Liver Physiol. (2004) 286(4):G613-G626.
76. MORISHITA TY, AYE PP, HARR BS, COBB CW, CLIFFORD JR: Evaluation of an avian-specific probiotic to reduce the colonization and shedding of Campylobacter jejuni in broilers. Avian Dis. (1997) 41(4):850-855.
77. VAHJEN W, MANNER K: The effect of a probiotic Enterococcus faecium product in diets of healthy dogs on bacteriological counts of Salmonella spp., Campylobacter spp. and Clostridium spp. in faeces. Arch. Tierernahr. (2003) 57(3):229-233.
78. JIN LZ, MARQUARDT RR, ZHAO X: A strain of Enterococcus faecium (18C23) inhibits adhesion of enterotoxigenic Escherichia coli K88 to porcine small intestine mucus. Appl. Environ. Microbiol. (2000) 66(10):4200-4204.
79. AUDISIO MC, OLIVER G, APELLA MC: Effect of different complex carbon sources on growth and bacteriocin synthesis of Enterococcus faecium. Int. J. Food Microbiol. (2001) 63(3):235-241.
80. HABERMANN W, ZIMMERMANN K, SKARABIS H, KUNZE R, RUSCH V: [Reduction of acute recurrence in patients with chronic recurrent hypertrophic sinusitis by treatment with a bacterial immunostimulant (Enterococcus faecalis Bacteriae of human origin]. Arzneimittelforschung (2002) 52(8):622-627.
81. JANSEN G, DEDDENS B, WILKINSON M, VAN DER WAAIJ D: Significant decrease of titres of circulating IgG after oral intake of a preparation of Enterococcus faecalis in a group often healthy volunteers. Infection (1993) 21(3):193-194.
82. LINAJE R, COLOMA MD, PEREZ-MARTINEZ G, ZUNIGA M: Characterization of faecal enterococci from rabbits for the selection of probiotic strains. J. Appl. Microbiol. (2004) 96(4):761-771.
83. MANNU L, PABA A, DAGA E et al.: Comparison of the incidence of virulence determinants and antibiotic resistance between Enterococcus faecium strains of dairy, animal and clinical origin. Int. J. Food Microbiol. (2003) 88(2-3):291-304.
84. SEMEDO T, SANTOS MA, LOPES MF et al.: Virulence factors in food, clinical and reference Enterococci: A common trait in the genus? Syst. Appl. Microbiol. (2003) 26(1):13-22.
85. HUFNAGEL M, KOCH S, KROPEC A, HUEBNER J: Opsonophagocytic assay as a potentially useful tool for assessing safety of enterococcal preparations. Int. J. Food Microbiol. (2003) 88(2-3):263-267.
86. GIRAFFA G: Functionality of enterococci in dairy products. Int. J. Food Microbiol. (2003) 88(2-3):215-222.
87. EATON TJ, GASSON MJ: Molecular screening of Enterococcus virulence determinants and potential for genetic exchange between food and medical isolates. Appl. Environ. Microbiol. (2001) 67(4):1628-1635.
88. MONTECALVO MA, DE LENCASTRE H, CARRAHER M et al.: Natural history of colonization with vancomycin-resistant Enterococcus faecium. Infect Control Hasp. Epidemiol (1995) 16(12):680-685.
89. BADEN LR, THIEMKE W, SKOLNIK A et al.: Prolonged colonization with vancomycin-resistant Enterococcus faecium in long-term care patients and the significance of 'clearance'. Clin. Infect. Dis. (2001) 33(10):1654-1660.
90. TENORIO AR, BADRI SM, SAHGAL NB et al.: Effectiveness of gloves in the prevention of hand carriage of vancomycin-resistant enterococcus species by health care workers after patient care. Clin. Infect. Dis. (2001) 32(5):826-829.
91. LIVORNESE LL JR, DIAS S, SAMEL C et al.: Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers. Ann. Intern. Med. (1992) 117(2):112-116.
92. NOSKIN GA, BEDNARZ P, SURIANO T, REINER S, PETERSON LR: Persistent contamination of fabric-covered furniture by vancomycin-resistant enterococci: implications for upholstery selection in hospitals. Am. J. Infect. Control (2000) 28(4):311-313.
93. BONILLA HF, ZERVOS MJ, KAUFFMAN CA: Long-term survival of vancomycin-resistant Enterococcus faecium on a contaminated surface. Infect. Control Hosp. Epidemiol. (1996) 17(12):770-772.
94. NO AUTHORS LISTED: Recommendations for preventing the spread of vancomycin resistance. Hospital Infection Control Practices Advisory Committee (HICPAC). Infect. Control Hosp. Epidemiol. (1995) 16(2):105-113.
95. MONTECALVO MA: Ramoplanin: a novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in high-risk patients. J. Antimicrob. Chemother. (2003) 51(Suppl. 3):iii31-iii35. Description of a promising new weapon against VRE colonisation.
96. HENNING KJ, DELENCASTRE H, EAGAN J et al.: Vancomycin-resistant Enterococcus faecium on a pediatric oncology ward: duration of stool shedding and incidence of clinical infection. Pediatr. Infect. Dis. J. (1996) 15(10):848-854.
97. PATEL R, ALLEN SL, MANAHAN JM et al.: Natural history of vancomycin-resistant enterococcal colonization in liver and kidney transplant recipients. Liver Transpl. (2001) 7(1):27-31.
98. TENDOLKAR PM, BAGHDAYAN AS, SHANKAR N: Pathogenic enterococci: new developments in the 21st century. Cell. Mol. Life Sci. (2003) 60(12):2622-2636.
99. KOCH S, HUFNAGEL M, THEILACKER C, HUEBNER J: Enterococcal infections: host response, therapeutic, and prophylactic possibilities. Vaccine (2004) 22(7):822-830.
100. SARTINGEN S, ROZDZINSKI E, MUSCHOLL-SILBERHORN A, MARRE R: Aggregation substance increases adherence and internalization, but not translocation, of Enterococcus faecalis through different intestinal epithelial cells in vitro. Infect. Immun. (2000) 68(10):6044-6047.
101. KREFT B, MARRE R, SCHRAMM U, WIRTH R: Aggregation substance of Enterococcus faecalis mediates adhesion to cultured renal tubular cells. Infect. Immun. (1992) 60(1):25-30.
102. VANEK NN, SIMON SI, JACQUES-PALAZ K et al.: Enterococcus faecalis aggregation substance promotes opsonin-independent binding to human neutrophils via a complement receptor type 3-mediated mechanism. FEMS Immunol. Med. Microbiol. (1999) 26(1):49-60.
103. SUSSMUTH SD, MUSCHOLL-SILBERHORN A, WIRTH R et al.: Aggregation substance promotes adherence, phagocytosis, and intracellular survival of Enterococcus faecalis within human macrophages and suppresses respiratory burst. Infect. Immun. (2000) 68(9):4900-4906.
104. ISENMANN R, SCHWARZ M, ROZDZINSKI E, MARRE R, BEGER HG: Aggregation substance promotes colonic mucosal invasion of Enterococcus faecalis in an ex vivo model. J. Surg. Res. (2000) 89(2):132-138.
105. OLMSTED SB, DUNNY GM, ERLANDSEN SL, WELLS CL: A plasmid-encoded surface protein on Enterococcus faecalis augments its internalization by cultured intestinal epithelial cells. J. Infect. Dis. (1994) 170(6):1549-1556.
106. WELLS CL, MOORE EA, HOAG JA et al.: Inducible expression of Enterococcus faecalis aggregation substance surface protein facilitates bacterial internalization by cultured enterocytes. Infect. Immun. (2000) 68(12):7190-7194.
107. CHOW JW, THAL LA, PERRI MB et al.: Plasmid-associated hemolysin and aggregation substance production contribute to virulence in experimental enterococcal endocarditis. Antimicrob. Agents Chemother. (1993) 37(11):2474-2477.
108. ISENMANN R, SCHWARZ M, ROZDZINSKI E et al.: Interaction of fibronectin and aggregation substance promotes adherence of Enterococcus faecalis to human colon. Dig. Dis. Sci. (2002) 47(2):462-468.
109. SCHLIEVERT PM, GAHR PJ, ASSIMACOPOULOS AP et al.: Aggregation and binding substances enhance pathogenicity in rabbit models of Enterococcus faecalis endocarditis. Infect. Immun. (1998) 66(1):218-223.
110. MCCORMICK JK, HIRT H, WATERS CM et al.: Antibodies to a surface-exposed, N-terminal domain of aggregation substance are not protective in the rabbit model of Enterococcus faecalis infective endocarditis. Infect. Immun. (2001) 69(5):3305-3314. Investigation of a therapeutic approach against a well-known virulence factor of enterococci.
111. CARPENTIER B, CERF O: Biofilms and their consequences, with particular reference to hygiene in the food industry. J. Appl. Bacteriol. (1993) 75(6):499-511.
112. KRISTICH CJ, LI YH, CVITKOVITCH DG, DUNNY GM: Esp-independent biofilm formation by Enterococcus faecalis. J. Bacteriol. (2004) 186(1):154-163.
113. TOLEDO-ARANA A, VALLE J, SOLANO C et al.: The enterococcal surface protein, Esp, is involved in Enterococcus faecalis biofilm formation. Appl. Environ. Microbiol. (2001) 67(10):4538-4545.
114. BALDASSARRI L, CECCHINI R, BERTUCCINI L et al.: Enterococcus spp. produces slime and survives in rat peritoneal macrophages. Med. Microbiol. Immunol. (Berl.) (2001) 190(3):113-120.
115. SU SH, EATON JW, VENEZIA RA, TANG L: Interactions of vancomycin resistant enterococci with biomaterial surfaces. ASAIO J. (1998) 44(6):770-775.
116. JOYANES P, PASCUAL A, MARTINEZ-MARTINEZ L, HEVIA A, PEREA EJ: In vitro adherence of Enterococcus faecalis and Enterococcus faecium to plastic biomaterials. Clin. Microbiol. Infect. (1999) 5(6):382-386.
117. JOYANES P, PASCUAL A, MARTINEZ-MARTINEZ L, HEVIA A, PEREA EJ: In vitro adherence of Enterococcus faecalis and Enterococcus faecium to urinary catheters. Eur. J. Clin. Microbiol. Infect. Dis. (2000) 19(2):124-127.
118. SANDOE JA, WITHERDEN IR, COVE JH, HERITAGE J, WILCOX MH: Correlation between enterococcal biofilm formation in vitro and medical-device-related infection potential in vivo. J. Med. Microbiol. (2003) 52(Pt 7):547-550. Important study demonstrating the clinical relevance of enterococcal biofilm formation in catheter adherence.
119. HUFNAGEL M, KOCH S, CRETI R, BALDASSARRI L, HUEBNER J: A putative sugar-binding transcriptional regulator in a novel gene locus in Enterococcus faecalis contributes to production of biofilm and prolonged bacteremia in mice. J. Infect. Dis. (2004) 189(3):420-430.
120. GIACOMETTI A, CIRIONI O, GOV Y et al.: RNA III inhibiting peptide inhibits in vivo biofilm formation by drug-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. (2003) 47(6):1979-1983.
121. BALABAN N, GOLDKORN T, NHAN RT et al.: Autoinducer of virulence as a target for vaccine and therapy against Staphylococcus aureus. Science (1998) 280(5362):438-440.
122. BALABAN N, COLLINS LV, CULLOR JS et al.: Prevention of diseases caused by Staphylococcus aureus using the peptide RIP. Peptides (2000) 21(9):1301-1311.
123. GOTTENBOS B, GRIJPMA DW, VAN DER MEI HC, FEIJEN J, BUSSCHER HJ: Antimicrobial effects of positively charged surfaces on adhering Gram-positive and Gram-negative bacteria. J. Antimicrob. Chemother. (2001) 48(1):7-13.
124. TILLER JC, LIAO CJ, LEWIS K, KLIBANOV AM: Designing surfaces that kill bacteria on contact. Proc. Natl. Acad. Sci. USA (2001) 98(11):5981-5985.
125. BOORGU R, DUBROW AJ, LEVIN NW et al.: Adjunctive antibiotic/anticoagulant lock therapy in the treatment of bacteremia associated with the use of a subcutaneously implanted hemodialysis access device. ASAIO J. (2000) 46(6):767-770.
126. KRISHNASAMI Z, CARLTON D, BIMBO L et al.: Management of hemodialysis catheter-related bacteremia with an adjunctive antibiotic lock solution. Kidney Int. (2002) 61(3):1136-1142.
127. MESSING B, PEITRA-COHEN S, DEBURE A, BELIAH M, BERNIER JJ: Antibiotic-lock technique: a new approach to optimal therapy for catheter-related sepsis in home-parenteral nutrition patients. JPEN J. Parenter. Enteral Nutr. (1988) 12(2):185-189.
128. CURTIN J, CORMICAN M, FLEMING G, KEELEHAN J, COLLERAN E: Linezolid compared with eperezolid, vancomycin, and gentamicin in an in vitro model of antimicrobial lock therapy for Staphylococcus epidermidis central venous catheter-related biofilm infections. Antimicrob. Agents Chemother. (2003) 47(10):3145-3148.
129. WILCOX MH, KITE P, MILLS K, SUGDEN S: In situ measurement of linezolid and vancomycin concentrations in intravascular catheter-associated biofilm. J. Antimicrob. Chemother. (2001) 47(2):171-175.
130. KRUEGER WA, KRUEGER-RAMECK S, KOCH S et al.: Assessment of the role of antibiotics and enterococcal virulence factors in a mouse model of extraintestinal translocation. Crit. Care Med. (2004) 32(2):467-471.
131. RESCIGNO M, URBANO M, VALZASINA B et al.: Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat. Immun. (2001) 2(4):361-367. Initial report of DC sampling of intestinal microflora and possible translocation pathway for colonising bacteria.
132. MACPHERSON AJ, UHR T: Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science (2004) 303(5664):1662-1665.
133. GEWIRTZ AT, MADARA JL: Periscope, up! Monitoring microbes in the intestine. Nat. Immunol. (2001) 2(4):288-290.
134. COQUE TM, PATTERSON JE, STECKELBERG JM, MURRAY BE: Incidence of hemolysin, gelatinase, and aggregation substance among enterococci isolated from patients with endocarditis and other infections and from feces of hospitalized and community-based persons. J. Infect. Dis. (1995) 171(5):1223-1229.
135. HAAS W, SHEPARD BD, GILMORE MS: Two-component regulator of Enterococcus faecalis cytolysin responds to quorum-sensing autoinduction. Nature (2002) 415(6867):84-87.
136. GALLEGOS MT, SCHLEIF R, BAIROCH A, HOFMANN K, RAMOS JL: Arac/XylS family of transcriptional regulators. Microbiol Mol. Biol. Rev. (1997) 61(4):393-410.
137. GIARD JC, VERNEUIL N, AUFFRAY Y, HARTKE A: Characterization of genes homologous to the general stress-inducible gene gls24 in Enterococcus faecalis and Lactococcus lactis. FEMS Microbiol. Lett. (2002) 206(2):235-239.
138. LARSON EL, EARLY E, CLOONAN P, SUGRUE S, PARIDES M: An organizational climate intervention associated with increased handwashing and decreased nosocomial infections. Behav. Med. (2000) 26(1):14-22.
139. DELISLE S, PERL TM: Vancomycin-resistant enterococci: a road map on how to prevent the emergence and transmission of antimicrobial resistance. Chest (2003) 123(5 Suppl.):504S-518S.